French blood products firm LFB spins out New York-based TG Therapeutics
This article was originally published in Scrip
Executive Summary
A new company, TG Therapeutics, based in New York City, is a spin-off of the French state-owned company LFB Biotechnologies, and has gained a worldwide licence to ublituximab from LFB.